The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Impact of 10-day decitabine vs standard intensive chemotherapy on HRQoL in older patients with AML
|
The phase III European Organization for Research and Treatment of Cancer (EORTC)-1301 AML21 trial (NCT02172872) assessed the safety and efficacy of 10-day decitabine vs standard 3+7 intensive chemotherapy in newly diagnosed, fit patients aged ≥60 years with acute myeloid leukemia (AML).1 The study design and primary results from this trial were reported previously by the AML Hub. This trial included health-related quality of life (HRQoL) as a secondary endpoint, and results from the HRQoL analysis were published in Blood by Efficace, et al.1 |
| Key learnings |
|
At 2 months, treatment with 10-day decitabine resulted in a lower risk of HRQoL deterioration compared with intensive chemotherapy (76% vs 88%; odds ratio, 0.43; 95% confidence interval, 0.24–0.76; p = 0.003). |
|
There were no statistically significant differences in the risk of HRQoL deterioration between decitabine and intensive chemotherapy after 6 or 12 months, suggesting both treatments have comparable long-term impacts on quality of life. |
|
Patients in the 3+7 arm who underwent allogeneic hematopoietic stem cell transplantation experienced clinically meaningful deterioration post-transplantation, relative to baseline, in the physical functioning, role functioning, fatigue, and burden of illness scales. In contrast, no clinically meaningful deteriorations were observed post-transplantation in the decitabine arm. |
|
When combined with the efficacy and safety results of this trial, the HRQoL findings suggest that decitabine may be preferable over intensive chemotherapy for newly diagnosed, older, fit patients with AML. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
